128 related articles for article (PubMed ID: 16981571)
1. [LIFE].
Hiwada K
Nihon Rinsho; 2006 Aug; 64 Suppl 6():408-13. PubMed ID: 16981571
[No Abstract] [Full Text] [Related]
2. Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Bourassa MG
J Am Coll Cardiol; 2005 Mar; 45(5):720-1. PubMed ID: 15734616
[No Abstract] [Full Text] [Related]
3. [CASE-J].
Fukui T
Nihon Rinsho; 2006 Aug; 64 Suppl 6():449-53. PubMed ID: 16981578
[No Abstract] [Full Text] [Related]
4. [E-COST].
Kanno Y; Suzuki H
Nihon Rinsho; 2006 Aug; 64 Suppl 6():480-5. PubMed ID: 16981581
[No Abstract] [Full Text] [Related]
5. [COPE trial].
Umemoto S; Kamiya A; Matsuzaki M; Ogihara T
Nihon Rinsho; 2006 Aug; 64 Suppl 6():470-4. PubMed ID: 16981580
[No Abstract] [Full Text] [Related]
6. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
8. [Study on cognition and prognosis in the elderly].
Kohara K
Nihon Rinsho; 2006 Aug; 64 Suppl 6():425-30. PubMed ID: 16981574
[No Abstract] [Full Text] [Related]
9. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Smebye ML; Iversen EK; Høieggen A; Flaa A; Os I; Kjeldsen SE; Olsen MH; Chattopadhyay A; Hille DA; Lyle PA; Devereux RB; Dahlöf B
Am J Cardiol; 2007 Sep; 100(5):855-9. PubMed ID: 17719333
[TBL] [Abstract][Full Text] [Related]
10. [VALUE].
Okura T; Higaki J
Nihon Rinsho; 2006 Aug; 64 Suppl 6():419-24. PubMed ID: 16981573
[No Abstract] [Full Text] [Related]
11. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
12. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
[TBL] [Abstract][Full Text] [Related]
13. [LIFE study proves preventive action. With losartan to do even more against stroke].
Baumgart P
MMW Fortschr Med; 2003; 145 Suppl 1():7-8. PubMed ID: 12958796
[No Abstract] [Full Text] [Related]
14. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
17. Renal and stroke protection in hypertensive patients at CV risk.
Cardiovasc J Afr; 2007; 18(5):337, 340. PubMed ID: 17985036
[No Abstract] [Full Text] [Related]
18. [VALISH].
Rakugi H; Ogihara T
Nihon Rinsho; 2006 Aug; 64 Suppl 6():454-8. PubMed ID: 16981579
[No Abstract] [Full Text] [Related]
19. Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Lyle PA
Expert Opin Pharmacother; 2004 Nov; 5(11):2311-20. PubMed ID: 15500378
[TBL] [Abstract][Full Text] [Related]
20. [Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
MMW Fortschr Med; 2002 May; 144(20):60-1. PubMed ID: 12119887
[No Abstract] [Full Text] [Related]
[Next] [New Search]
